Cite
Socinski MA, Sandler AB, Miller LL, et al. Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial. Clin Lung Cancer. 2001;2:S26-33doi: 10.3816/clc.2001.s.005.
Socinski, M. A., Sandler, A. B., Miller, L. L., Locker, P. K., Hanover, C. K., Elfring, G. L., Israel, V. K., Pirotta, N., & Natale, R. B. (2001). Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial. Clinical lung cancer, 2S26-33. https://doi.org/10.3816/clc.2001.s.005
Socinski, M A, et al. "Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial." Clinical lung cancer vol. 2 (2001): S26-33. doi: https://doi.org/10.3816/clc.2001.s.005
Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB. Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial. Clin Lung Cancer. 2001 May;2:S26-33. doi: 10.3816/clc.2001.s.005. PMID: 14725727.
Copy
Download .nbib